Fol. Biol. 2020, 66, 86-90

Transfer Factor as an Option for Managing the COVID-19 Pandemic

D. Viza1, G. Pizza2, C. De Vinci2, G. Brandi3, Dharam Ablashi4

1Immunobiology Laboratory, Faculté de Médicine, Paris 6, France
2Immunotherapy dept., S. Orsola-Malpighi University Hospital, Bologna, Italy
3Medical Oncology, S. Orsola-Malpighi University Hospital, Bologna, Italy
4HHV-6 Foundation, Santa Barbara, CA, USA

Received June 2020
Accepted July 2020

Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mortality. As no treatment or vaccine may become available before many months, and because occurrence of similar pandemics is only a matter of time, arguments are presented here for testing the effect of transfer factor (TF), an immunomodulator devoid of toxicity, which has been extensively studied in the past for the treatment and prevention of viral infections.


45 live references